Multimodality treatment for recurrent neuroblastoma in the central nervous system

alexandrossfakianakis shared this article with you from Inoreader Multimodality treatment for recurrent neuroblastoma in the central nervous system via Pediatric Blood & Cancer Abstract Survival for patients with recurrent central nervous system (CNS) neuroblastoma remains poor. A single-institutional study demonstrated the potential of multimodality therapy, including compartmental intrathecal radioimmunotherapy (cRIT) with 131I-3F8 or 131I-8H9 to increase the survival of neuroblastoma patients with CNS relapse. However, not all patients are able to receive this therapy. We report three patients with CNS neuroblastoma who remain disease-free 3–9 years after receiving multimodality treatment without cRIT. Additional studies to identify patients most likely to benefit from cRIT are warranted. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.